603 related articles for article (PubMed ID: 15750214)
1. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease.
de la Monte SM; Wands JR
J Alzheimers Dis; 2005 Feb; 7(1):45-61. PubMed ID: 15750214
[TBL] [Abstract][Full Text] [Related]
2. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?
Steen E; Terry BM; Rivera EJ; Cannon JL; Neely TR; Tavares R; Xu XJ; Wands JR; de la Monte SM
J Alzheimers Dis; 2005 Feb; 7(1):63-80. PubMed ID: 15750215
[TBL] [Abstract][Full Text] [Related]
3. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine.
Rivera EJ; Goldin A; Fulmer N; Tavares R; Wands JR; de la Monte SM
J Alzheimers Dis; 2005 Dec; 8(3):247-68. PubMed ID: 16340083
[TBL] [Abstract][Full Text] [Related]
4. The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: possible therapeutic implications.
Zemva J; Schubert M
CNS Neurol Disord Drug Targets; 2014 Mar; 13(2):322-37. PubMed ID: 24059318
[TBL] [Abstract][Full Text] [Related]
5. Central insulin and insulin-like growth factor-1 signaling: implications for diabetes associated dementia.
Zemva J; Schubert M
Curr Diabetes Rev; 2011 Sep; 7(5):356-66. PubMed ID: 21916834
[TBL] [Abstract][Full Text] [Related]
6. The impairment of insulin signaling in Alzheimer's disease.
Candeias E; Duarte AI; Carvalho C; Correia SC; Cardoso S; Santos RX; Plácido AI; Perry G; Moreira PI
IUBMB Life; 2012 Dec; 64(12):951-7. PubMed ID: 23129399
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease.
de la Monte SM; Tong M; Lester-Coll N; Plater M; Wands JR
J Alzheimers Dis; 2006 Sep; 10(1):89-109. PubMed ID: 16988486
[TBL] [Abstract][Full Text] [Related]
8. Insulin signaling: An opportunistic target to minify the risk of Alzheimer's disease.
Pardeshi R; Bolshette N; Gadhave K; Ahire A; Ahmed S; Cassano T; Gupta VB; Lahkar M
Psychoneuroendocrinology; 2017 Sep; 83():159-171. PubMed ID: 28624654
[TBL] [Abstract][Full Text] [Related]
9. Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer's Disease.
de la Monte SM; Tong M; Schiano I; Didsbury J
J Alzheimers Dis; 2017; 55(2):849-864. PubMed ID: 27802237
[TBL] [Abstract][Full Text] [Related]
10. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease.
Lester-Coll N; Rivera EJ; Soscia SJ; Doiron K; Wands JR; de la Monte SM
J Alzheimers Dis; 2006 Mar; 9(1):13-33. PubMed ID: 16627931
[TBL] [Abstract][Full Text] [Related]
11. Impaired insulin signaling and the pathogenesis of Alzheimer's disease.
Revill P; Moral MA; Prous JR
Drugs Today (Barc); 2006 Dec; 42(12):785-90. PubMed ID: 17285151
[TBL] [Abstract][Full Text] [Related]
12. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Chen Z; Zhong C
Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
[TBL] [Abstract][Full Text] [Related]
13. Brain insulin, insulin-like growth factor 1 and glucagon-like peptide 1 signalling in Alzheimer's disease.
Ferreira ST
J Neuroendocrinol; 2021 Apr; 33(4):e12959. PubMed ID: 33739563
[TBL] [Abstract][Full Text] [Related]
14. Middle-Aged Diabetic Females and Males Present Distinct Susceptibility to Alzheimer Disease-like Pathology.
Candeias E; Duarte AI; Sebastião I; Fernandes MA; Plácido AI; Carvalho C; Correia S; Santos RX; Seiça R; Santos MS; Oliveira CR; Moreira PI
Mol Neurobiol; 2017 Oct; 54(8):6471-6489. PubMed ID: 27730513
[TBL] [Abstract][Full Text] [Related]
15. Insulin resistance and Alzheimer's disease: molecular links & clinical implications.
Neumann KF; Rojo L; Navarrete LP; Farías G; Reyes P; Maccioni RB
Curr Alzheimer Res; 2008 Oct; 5(5):438-47. PubMed ID: 18855585
[TBL] [Abstract][Full Text] [Related]
16. Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease.
Velazquez R; Tran A; Ishimwe E; Denner L; Dave N; Oddo S; Dineley KT
Neurobiol Aging; 2017 Oct; 58():1-13. PubMed ID: 28688899
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer-associated neuronal thread protein mediated cell death is linked to impaired insulin signaling.
de la Monte SM; Wands JR
J Alzheimers Dis; 2004 Jun; 6(3):231-42. PubMed ID: 15201478
[TBL] [Abstract][Full Text] [Related]
18. Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease.
de la Monte SM; Re E; Longato L; Tong M
J Alzheimers Dis; 2012; 30 Suppl 2(0 2):S217-29. PubMed ID: 22297646
[TBL] [Abstract][Full Text] [Related]
19. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes.
Gupta A; Bisht B; Dey CS
Neuropharmacology; 2011 May; 60(6):910-20. PubMed ID: 21277873
[TBL] [Abstract][Full Text] [Related]
20. Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease.
Ferreira ST; Clarke JR; Bomfim TR; De Felice FG
Alzheimers Dement; 2014 Feb; 10(1 Suppl):S76-83. PubMed ID: 24529528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
